Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Recruiting
AstraZeneca
Phase 2
2015-06-01
Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse
type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment,
such as metformin. Recent data (animal and human) suggest that metformin may attenuate the
favorable benefits of exercise training. In light of the physiological mechanism of
Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that
rather than inhibit, it will augment the favorable adaptations to exercise training.
Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Recruiting
Christopher Bell
Phase 2
2015-06-01
Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse
type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment,
such as metformin. Recent data (animal and human) suggest that metformin may attenuate the
favorable benefits of exercise training. In light of the physiological mechanism of
Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that
rather than inhibit, it will augment the favorable adaptations to exercise training.
Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes
Recruiting
Gulf Regional Research & Educational Services, LLC
Phase 4
2015-02-01
Dapagliflozin has been shown to lower clinic systolic and diastolic blood pressure in
patients with type 2 diabetes mellitus. The exact mechanism(s) by which dapagliflozin lowers
clinic SBP is unknown. The primary objective of the study is to determine the effect of
dapagliflozin , 10 mg daily, on parameters of arterial stiffness: aPWV, augmentation index
(AI), 24-hour blood pressure patterns, SBP, and pulse pressure. Urinary sodium excretion,
and Intravascular volume status will be recorded. The study will involve 21 subjects for a
duration of 16 weeks.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
